Outcome of low dose daily versus standard alternate day prednisolone for frequent relapse nephrotic syndrome in children
DOI:
https://doi.org/10.18203/2349-3291.ijcp20260817Keywords:
Frequent-relapse nephrotic syndrome, Paediatric nephrologyAbstract
Background: Nephrotic syndrome is a common chronic glomerular disorder in children, with frequent relapses causing significant clinical and psychosocial burden. Prednisolone remains the cornerstone of therapy, typically administered on an alternate-day schedule for maintenance. However, low daily-dose regimens may improve relapse control with fewer adverse effects, particularly in resource-limited settings.
Methods: This quasi-experimental study included 72 children aged 2-12 years with FRNS treated at the National Institute of Kidney Diseases and Urology, Dhaka, between August 2022 and August 2024. Participants received either daily low-dose prednisolone (0.2 mg/kg; Group A, n=31) or alternate-day prednisolone (0.5 mg/kg; Group B, n=32) for six months. Clinical features, anthropometric measurements, laboratory findings, relapse frequency, and steroid-related adverse effects were assessed at baseline, 3 months, and 6 months. Data were analyzed using independent T-tests and chi-square tests, with p<0.05 considered significant.
Results: Baseline characteristics were comparable. At 6 months, oedema, ascites, and significant proteinuria were more frequent in Group B (70% vs. 41.4%, p=0.027). Group A had a lower cumulative prednisolone dose (60.57±24.79 mg/kg vs. 76.01±14.21 mg/kg, p=0.005), fewer Cushingoid features (3.4% vs. 20%, p=0.049), better BMI preservation, lower relapse rates (41.4% vs. 70%, p=0.027), and higher remission rates (58.6% vs. 30%, p=0.027).
Conclusions: Daily low-dose prednisolone appears more effective and safer than the standard alternate-day regimen in maintaining remission in children with FRNS.
Metrics
References
Bagga A, Srivastava RN. Nephrotic syndrome. Pediatr Nephrol. 2016;4:159-200. DOI: https://doi.org/10.5005/jp/books/12792_12
Baudouin V, Alberti C, Lapeyraque AL, Bensman A, André JL, Broux F, et al. Mycophenolate mofetil for steroid-dependent nephrotic syndrome: A phase II Bayesian trial. Pediatr Nephrol. 2012;27(3):389-96. DOI: https://doi.org/10.1007/s00467-011-2006-7
Brodehl J. Alternate-day prednisone is more effective than intermittent prednisone in frequently relapsing nephrotic syndrome: A report of “Arbeitsgemeinschaft für pädiatrische nephrologie”. Eur J Pediatr. 1981;135(3):229-37. DOI: https://doi.org/10.1007/BF00442096
Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629-39. DOI: https://doi.org/10.1016/S0140-6736(03)14184-0
Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood: Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr. 1988;27(8):387-92. DOI: https://doi.org/10.1177/000992288802700807
Emma F, Sesto A, Rizzoni G. Long-term linear growth of children with severe steroid-responsive nephrotic syndrome. Pediatr Nephrol. 2003;18(8): 783-8. DOI: https://doi.org/10.1007/s00467-003-1176-3
Esezobor C, Ademola AD, Adetunji AE, Anigilaje EA, Batte A, Jiya-Bello FN, et al. Management of idiopathic childhood nephrotic syndrome in sub-Saharan Africa: Ibadan consensus statement. Kidney Int. 2021;99(1):59-67. DOI: https://doi.org/10.1016/j.kint.2020.07.045
Garibotto G, Giannoni M, Salvatore F. Complications of the nephrotic syndrome. G Ital Nefrol. 2011;20(1):49-60.
Gulati A, Sinha A, Sreenivas V, Math A, Hari P, Bagga A. Daily corticosteroids reduce infection-associated relapses in frequently relapsing nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6(1):63-9. DOI: https://doi.org/10.2215/CJN.01850310
Gupta S, Rana S, Das A, Kumar V, Rathi M, Kohli HS, et al. Case Report Intestinal Tuberculosis: A Rare Case of Massive Gastrointestinal Bleed in a Post ‑ Renal Transplant Recipient. Indian J Nephrol. 2019;29(2):132-4. DOI: https://doi.org/10.4103/ijn.IJN_360_17
Hahn D, Samuel SM, Willis NS, Craig JC, Hodson EM. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2020;2020(8):CD002256. DOI: https://doi.org/10.1002/14651858.CD001533.pub6
Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2005;25(1): CD002256. DOI: https://doi.org/10.1002/14651858.CD001533.pub3
Iijima K, Swiatecka-Urban A, Niaudet P, Bagga A. Steroid-Sensitive Nephrotic Syndrome. Pediatric Nephrology. 2022;351-86. DOI: https://doi.org/10.1007/978-3-030-52719-8_92
Khanna R. Clinical Presentation and management of Glomerular Diseases. sci med. 2011;108(1):33-6.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. 2021.Available at: https://kdigo.org/. Accessed on 22 November 2025.
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):1-276.
Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2(2):1-274.
Downloads
Published
How to Cite
Issue
Section
